Guillain-Barre Syndrome-Pipeline Insights, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 84755
Related Topics: FDA

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Guillain-Barre
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s, “ Guillain-Barre Syndrome-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Guillain-Barre Syndrome. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Guillain-Barre Syndrome. DelveInsight’s Report also assesses the Guillain-Barre Syndrome therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

• The report provides competitivepipeline landscape of Guillain-Barre Syndrome

• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

• Coverage of the Guillain-Barre Syndrome pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

• The report reviews key players involved in the therapeutics development for Guillain-Barre Syndrome and also provide company profiling

• The report also gives the information of dormant and discontinued pipeline projects

• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time - 48-72 Hours

Table of Contents
for Guillain-Barre Syndrome-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Guillain-Barre Syndrome-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Guillain-Barre Syndrome, 2017

• Number of Products under Development by Companies

• Comparative Analysis by Filed and Phase III Products, 2017

• Comparative Analysis Phase II Products, 2017

• Comparative Analysis Phase I and IND Filed Products, 2017

• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017

• Drug Candidates Profiles

• Guillain-Barre Syndrome Assessment by Monotherapy Products

• Guillain-Barre Syndrome Assessment by Combination Products

• Guillain-Barre Syndrome Assessment by Route of Administration

• Guillain-Barre Syndrome Assessment by Stage and Route of Administration

• Guillain-Barre Syndrome Assessment by Molecule Type

• Guillain-Barre Syndrome Assessment by Stage and Molecule Type

• Guillain-Barre Syndrome Therapeutics – Discontinued Products

• Guillain-Barre Syndrome Therapeutics – Dormant Products

• Products under Development by Companies, 2017

List Of Figures, Charts and Diagrams
in Guillain-Barre Syndrome-Pipeline Insights, 2017 [Report Updated: 30-05-2017]

• Number of Products under Development for Guillain-Barre Syndrome, 2017

• Filed and Phase III Products, 2017

• Phase II Products, 2017

• Phase I and IND Filed Products, 2017

• Discovery and Pre-Clinical Stage Products, 2017

• Guillain-Barre Syndrome Assessment by Monotherapy Products

• Guillain-Barre Syndrome Assessment by Combination Products

• Guillain-Barre Syndrome Assessment by Route of Administration

• Guillain-Barre Syndrome Assessment by Stage and Route of Administration

• Guillain-Barre Syndrome Assessment by Molecule Type

• Guillain-Barre Syndrome Assessment by Stage and Molecule Type

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

84755 | DIPR2017269

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2017
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial re...
30 Aug 2017 by Global Data USD $2,500 More Info
Guillain-Barre Syndrome - Pipeline Insight, 2017
DelveInsight’s, “Guillain-Barre Syndrome-Pipeline Insights, 2017”, report provides comprehensive ins...
31 Jul 2017 by Delve Insight USD $1,250 More Info
Guillain-Barre Syndrome - Pipeline Insight, 2017
DelveInsight’s, “Guillain-Barre Syndrome-Pipeline Insights, 2017”, report provides comprehensive ins...
31 Jul 2017 by Delve Insight USD $1,250 More Info
Guillain - Epidemiology Forecast To 2023
DelveInsight “Guillain - Epidemiology Forecast To 2023” provides an overview of the epidemiology tre...
31 May 2017 by Delve Insight USD $2,750 More Info
Guillain-Barre Syndrome (GBS)-Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Guillain-Barre Syndrome (GB...
30 May 2017 by Delve Insight USD $4,950 More Info
Malaysia Intravenous Immunoglobulin (IVIG) Market by Product Types (IgG, IgA, IgM, IgE and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Immune Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barré Syndrome, Kawasaki Disease,
CHAPTER 1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. KEY BENEFITS FOR STAKEHOLDERS1.3. KEY MARKET SEGME...
24 May 2017 by Allied Market Research USD $2,850 More Info
Guillain-Barre Syndrome - Pipeline Review, H1 2017
Guillain-Barre Syndrome - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutic...
09 May 2017 by Global Markets Direct USD $2,000 More Info
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2016
Guillain-Barre Syndrome Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial re...
21 Sep 2016 by Global Data USD $2,500 More Info
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2016
Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial re...
30 Jun 2016 by Global Data USD $2,500 More Info
IVIG Market: By Application (Hypogammaglobulinemia, CIDP, Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome), By Route of Administration (Intravenous, Subcutaneous), By Geography-Forecast (2016-2021)
Immunoglobulin refers to the breakdown of blood plasma that contains antibody and Intravenous immuno...
26 Feb 2016 by USD $5,250 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...